Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2028-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter，randomized, open label, active-controlled, parallel-group study
comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and
Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)